What is Puma Biotechnology?
Headquartered in Los Angeles, California, Puma Biotechnology, Inc. operates as a specialized biopharmaceutical entity dedicated to the rigorous development of drug candidates currently in the clinical-testing phase. The company maintains a primary focus on oncology, specifically targeting the treatment of various aggressive forms of cancer. By leveraging a robust research and development framework, Puma Biotechnology occupies a critical niche in the life sciences sector, aiming to bridge the gap between laboratory innovation and patient-centric therapeutic solutions. Its market position is defined by its commitment to addressing high-unmet medical needs through precision medicine and clinical excellence.
How much funding has Puma Biotechnology raised?
Puma Biotechnology has raised a total of $840.4M across 7 funding rounds:
Share Placement
$55M
Share Placement
$60M
Stock Offering
$129.1M
Stock Offering
$129.3M
Stock Offering
$205M
Stock Offering
$162M
Debt
$100M
Share Placement (2011): $55M with participation from Orbimed Private Investments, H&Q Life Science Investors, Tekla Healthcare Opportunities, Brookside Capital, Jennison Associates, T. Rowe Price Associates, and Adage Capital Management
Share Placement (2011): $60M led by Tekla Healthcare Opportunities, Brookside Capital, Orbimed Private Investments, H&Q Life Science Investors, Jennison Associates, T. Rowe Price Associates, and Adage Capital Management
Stock Issuance/Offering (2012): $129.1M supported by Undisclosed
Stock Issuance/Offering (2014): $129.3M featuring Undisclosed
Stock Issuance/Offering (2015): $205M backed by Undisclosed
Stock Issuance/Offering (2016): $162M with participation from Undisclosed
Debt (2017): $100M led by Silicon Valley Bank and Oxford Finance
Key Investors in Puma Biotechnology
Tekla Healthcare Opportunities
Aberdeen Investments is a global specialist asset manager dedicated to providing investment solutions across various asset classes, catering to individual investors, financial advisors, and institutional clients.
Brookside Capital
Bain Capital is a global private investment firm that specializes in private equity, growth and venture capital, credit, and real assets, partnering with visionary leaders to transform businesses.
Jennison Associates
Founded in 1969, Jennison Associates offers a range of equity and fixed income investment services across distribution channels and is headquartered in New York, NY.
What's next for Puma Biotechnology?
Looking ahead, the infusion of capital from the recent strategic investment will likely be directed toward accelerating the clinical trial milestones and expanding the regulatory footprint of its core therapeutic assets. As the company transitions through its current lifecycle stage, the focus remains on optimizing operational efficiency and strengthening its balance sheet to support potential commercial launches. Investors are closely monitoring the firm's ability to translate clinical data into regulatory approvals, which remains the primary catalyst for future valuation growth. The strategic deployment of these funds will be pivotal in maintaining the company's competitive edge within the highly volatile and capital-intensive biopharmaceutical landscape.
See full Puma Biotechnology company page
